Neuroblastoma Clinical Trial
— PsyRareCareOfficial title:
Psychosocial Situation of Children With Rare Solid Abdominal Tumors and Their Families
Verified date | June 2024 |
Source | Universitätsklinikum Hamburg-Eppendorf |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Families of children with rare diseases (i.e., not more than 5 out of 10.000 people are affected) are often highly burdened with fears, insecurities and concerns regarding the affected child and his/her siblings. The aim of the present research project is to examine the psychosocial burden of the children with rare solid abdominal tumors and their family in order to draw attention to a possible psychosocial care gap in this population.
Status | Completed |
Enrollment | 100 |
Est. completion date | March 31, 2023 |
Est. primary completion date | March 31, 2023 |
Accepts healthy volunteers | |
Gender | All |
Age group | 1 Month to 17 Years |
Eligibility | Inclusion Criteria (families of rare disease): - Family with at least one child between 0 and 17 years with rare solid abdominal tumors. - Consent to participate in the study. - Sufficient knowledge of the German language of parents and children. Exclusion Criteria (families of rare disease): - Severe acute physical, mental and/or cognitive impairment of the child, so that the questionnaire survey does not appear possible and/or unreasonable at this stage. Inclusion Criteria (control group): - Family with at least one child between 0 and 17 years who have undergone a surgical procedure in the first 3 years of life that does not cause chronic complaints - Consent to participate in the study. - Sufficient knowledge of the German language of parents and children. Exclusion Criteria (control group): - Families of children with a congenital or chronic disease. |
Country | Name | City | State |
---|---|---|---|
Germany | University Medical Center Hamburg-Eppendorf | Hamburg | |
Germany | University Medical Center Mannheim | Mannheim | Baden-Württemberg |
Lead Sponsor | Collaborator |
---|---|
Universitätsklinikum Hamburg-Eppendorf |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quality of Life of the parents (EQ-5D) | Quality of Life (QoL) of the parents, assessed from the perspective of the parents by the instrument "European Quality of Life Five Dimension" (EQ-5D; Hinz et al., 2006). The instrument consists of 5 dimensions, which are answered on a three-point scale. Higher scores indicate greater QoL. | 1 minutes | |
Primary | Health-related Quality of Life of the parents (SF-12) | Health-related Quality of Life (HRQoL) of the parents, assessed from the perspective of the parents by the "Short-Form-12" (SF-12; Morfeld, Kirchberger & Bullinger, 2011). The instrument consists of 12 items. Higher scores indicate greater HRQoL. | 4 minutes | |
Primary | Severity of depression (PHQ-9) | Severity of depression, will be assessed with the 9-question Patient Health Questionnaire (PHQ-9; Löwe et al., 2015). The instrument consists of 9 items. Higher scores indicate greater depression levels. | 2 minutes | |
Primary | Severity of generalized anxiety disorder | Generalizied Anxiety Disorder Scale-7 (GAD-7; Spitzer, Kroenke & Lo¨we, 2006). The instrument consists of 7 items. Higher score indicate greater anxiety levels. | 1 minutes | |
Primary | Mental health of the parents (BSI-18) | Mental health of the parents, assessed from the perspective of the parents by the "Brief Symptom Inventory-18" (BSI-18; Spitzer et al., 2011). The instrument consists of 18 items, which are answered on a five-point Likert scale (0 to 4). Higher BSI scores indicate greater psychological distress. | 4 minutes | |
Primary | Health-related quality of life of the chronically-ill children/adolescents (Peds-QL 4.0) | Health-related quality of life of the chronically-ill children/adolescents, assessed from the perspective of the child/adolescent (from 10 years of age) and from the perspective of the parents by the "Pediatric Quality of Life Inventory 4.0" (Peds-QL 4.0; (Varni, Seid, & Kurtin, 2001). Items will be linearly transformed to a scale of 0 to 100, with higher scores indicating better HRQoL. | 4 minutes | |
Primary | Psychiatric disorders of the chronically-ill children/adolescents (SDQ) | Psychiatric disorders of the chronically-ill children/adolescents assessed perspective of the child/adolescent and from the perspective of the parents by the "Strengths and Difficulties Questionnaire" (SDQ; Klasen, Woerner, Rothenberger, & Goodman, 2003). Items are rated on a three-point Likert scale (0 to 2). Higher scores represent greater psychopathology or greater prosocial behavior. | 4 minutes | |
Secondary | Social support of the parents, of the chronically-ill children/adolescents (OSSS) | Social support of the parents, of the chronically-ill children/adolescents and of the siblings, assessed from the perspective of the parents, of the chronically-ill children/adolescents and from the sibling, respectively, by the "Oslo Social Support Scale" (OSSS; Dalgard, 2006). The sum score ranges from 3 to 14. The higher the sum score, the stronger the social support | 3 minutes | |
Secondary | Coping of the parents (CHIP-D) | Coping of the parents, assessed from the perspective of the parents by the German version of the "Coping Health Inventory for Parents" (CHIP-D; McCubbin, McCubbin, Cauble & Goldbeck, 2001). Items are rated on a four-point Likert scale (0 to 3). Higher scores represent greater use of the respective coping pattern. | 3 minutes | |
Secondary | Family relationships, family dynamics and functionality (FB-A) | Family relationships, family dynamics and functionality, assessed from the perspective of the parents, of the chronically-ill children/adolescents and from the sibling, respectively by "Familienbögen" (FB-A; Cierpka & Frevert, 1994). Items are rated on a four-point Likert scale (0 to 3) | 3 minutes | |
Secondary | Familial predispositions (FaBel) | familial predispositions assessed from the perspective of the parents by the "Familien-Belastungs-Fragebogen" (FaBel; Ravens-Sieberer, 2001). Items are rated on a four-point Likert scale ranging from 1 (is not right at all) to 4 (is completely right). | 3 minutes | |
Secondary | Satisfaction with the relationship and parenting relationship of the parents (PFB) | Satisfaction with the relationship and parenting relationship of the parents, assessed from the perspective of the parents by the "Partnerschaftsfragebogen" (PFB; Hahlweg, 2016). | 4 minutes | |
Secondary | Parent-child communication (PACS) | Parent-child communication was assessed from the perspective of the child/adolescent and from the perspective of the parents by the "Parent-Adolescent Communication Scale" (PACS; Barnes & Olsen, 1982). Items are rated on a five-point Likert scale. | 4 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00492167 -
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
|
Phase 1 | |
Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03107988 -
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
|
Phase 1 | |
Recruiting |
NCT04253015 -
A Post-Authorisation Safety Study Patient Registry of Patients With Neuroblastoma Being Treated With Dinutuximab Beta
|
||
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03273712 -
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
|
Phase 2 | |
Recruiting |
NCT02933333 -
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
|
Phase 4 | |
Recruiting |
NCT00588068 -
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
|
||
Recruiting |
NCT04301843 -
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
|
Phase 2 | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Recruiting |
NCT04040088 -
An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors
|
Early Phase 1 | |
Recruiting |
NCT06057948 -
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
|
Phase 2 | |
Not yet recruiting |
NCT06335745 -
PediCARE Health Equity Intervention in High-Risk Neuroblastoma
|
N/A | |
Recruiting |
NCT02559778 -
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
|
Phase 2 | |
Completed |
NCT02441062 -
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
|
Phase 2 | |
Active, not recruiting |
NCT02245997 -
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma
|
N/A | |
Not yet recruiting |
NCT01156350 -
Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma
|
Phase 2 | |
Active, not recruiting |
NCT01192555 -
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT01222780 -
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
|
Phase 1 |